The Ohio State University Research Foundation

The Ohio State University Research Foundation (OSURF) is the legal and administrative entity that manages the research enterprise for The Ohio State University. Founded in 1934, it provides essential support for the university's research community by handling grant administration, compliance, and the commercialization of intellectual property. OSURF is a major hub for life sciences innovation, particularly through the Wexner Medical Center and the Comprehensive Cancer Center (OSUCCC – James), facilitating the transition of academic discoveries into the private sector. The foundation has been instrumental in the development of landmark therapies, including the gene therapy Zolgensma and the oncology drug Ibrutinib. Through its Drug Development Institute (DDI), OSURF maintains a robust pipeline of early-stage therapeutics and supports numerous biotech startups in fields such as immuno-oncology and rare genetic disorders.